In a recent interview Dr. Neil Shore is enthusiastic about the significance of the approval of Adstiladrin for BCG-unresponsive NMIBC patients, it had a durable complete response at 24 months of around 20%.
"This is really great, because for these patients, who have CIS, who again, are BCG- unresponsive, what one would be potentially contemplating, or having the discussion with their patients, is potential cystectomy""
TLD1433 PDT could end up achieving a 40% durable CR - double that of Adstiladrins 20% rate
I only hope that experts like Dr. Shore will be as enthusiastic about TLD1433 PDT when it is finally approved as it may help twice as many patients save their bladders